AZD1236 + Placebo

Phase 2Withdrawn

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cystic Fibrosis

Conditions

Cystic Fibrosis

Trial Timeline

Dec 1, 2009 → Aug 1, 2010

NCT ID

NCT00812045

About AZD1236 + Placebo

AZD1236 + Placebo is a phase 2 stage product being developed by AstraZeneca for Cystic Fibrosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00812045. Target conditions include Cystic Fibrosis.

What happened to similar drugs?

20 of 20 similar drugs in Cystic Fibrosis were approved

Approved (20) Terminated (7) Active (0)

✅CefiderocolShionogiApproved

✅CREONAbbVieApproved

✅Pancrelipase + PancrelipaseAbbVieApproved

✅Tedizolid PO + Tedizolid IVMerckApproved

✅Alendronate + PlaceboMerckApproved

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

✅Ceftolozane/TazobactamMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00812045	Phase 2	Withdrawn	Dec 1, 2009	Aug 1, 2010	Cystic Fibrosis
NCT00758459	Phase 2	Completed	Sep 1, 2008	Mar 1, 2009	Chronic Obstructive Pulmonary Disease
NCT00758706	Phase 2	Completed	Sep 1, 2008	May 1, 2009	Chronic Obstructive Pulmonary Disease

Competing Products

20 competing products in Cystic Fibrosis

See all competitors

Product	Company	Stage	Hype Score
VX-522 mRNA therapy + IVA	Moderna	Phase 1/2	36
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	17
Enfortumab Vedotin	Astellas Pharma	Phase 2	42
Cefiderocol	Shionogi	Approved	43
Lenvatinib	Eisai	Phase 2	39
Lenvatinib + Pembrolizumab	Eisai	Phase 2	39
CREON	AbbVie	Approved	43
Pancrelipase + Pancrelipase	AbbVie	Approved	43
Creon IR + Creon® (DR/GR)	AbbVie	Phase 2	35
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222	AbbVie	Phase 2	35
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119	AbbVie	Phase 2	27
Benralizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	32
AZD5634 for inhalation + AZD5634 for infusion	AstraZeneca	Phase 1	29
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD9668 + AZD9668 Placebo equivalent	AstraZeneca	Phase 2	35
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	35